UK Veterinary Expert Sounds Alarm Over Controversial Canine Pain Drug
A prominent British veterinarian has issued a stark warning regarding a new pharmaceutical treatment for dogs, following disturbing reports from the United States that associate the medication with the premature deaths of hundreds of pets. Dr Nick Thompson, a globally recognised authority on canine nutrition, has implored fellow veterinary professionals to conduct thorough research before administering the contentious drug to animals under their care.
The 'Wonder Drug' with a Dark Side
Librela, marketed as Solensia for feline patients, is a monthly injectable treatment designed to alleviate pain stemming from osteoarthritis in dogs. It has been hailed by some as a revolutionary 'wonder drug', with numerous five-star reviews praising it as 'liquid gold' and a 'game changer' for pets suffering from debilitating joint conditions. Many owners have reported remarkable improvements, describing their dogs regaining youthful energy and mobility after years of discomfort.
However, a growing chorus of campaigners and distressed pet owners contends that the drug carries severe, potentially fatal risks. They report that many animals are experiencing horrific side effects, including serious neurological complications that have, in some cases, led to death or necessitated euthanasia.
Disturbing Pattern of Adverse Reactions
Pet owners are documenting a range of alarming symptoms in dogs following just one or two doses of Librela. These include seizures, sudden hind limb collapse, urinary incontinence, ataxia (which impairs coordination and balance), and various other neurological disorders. The situation has become so dire that some owners have been forced to make the heartbreaking decision to put their beloved companions to sleep after they became critically ill post-treatment.
Dr Thompson, founder of Holistic Vet Ltd, explained the potential mechanism behind these issues. 'Librela would have maximum clinical effect in the most painful areas affected by osteoarthritis,' he stated. 'But as a systemic treatment, one that's injected into a dog's system, it has the potential to affect many other tissues and parts of the body too. This could account for the range of neurological issues being reported by owners. In theory, the nerves serving any part of a dog's body could be adversely affected by the drug.'
He emphasised the critical need for informed consent, adding: 'Vets and owners need to be fully informed so they can decide if it's a risk worth taking in their specific circumstances.'
Alarming Statistics from US Regulators
The scale of the problem is underscored by data from the United States Food and Drug Administration (FDA). Between May 2023 and June 2025, the FDA recorded nearly 14,000 adverse events in dogs following Librela administration. Tragically, within that total, 2,300 pets died after receiving the drug.
In December 2024, the FDA took formal action, issuing a letter to American veterinarians that explicitly listed Librela as having serious side effects, including ataxia, seizures, neurological issues, urinary incontinence, and, in severe instances, death or euthanasia.
Dr Thompson highlighted a concerning disparity in information sharing. 'This FDA list is based on recorded adverse reactions which include the same side effects as being reported by UK dog owners,' he noted. 'It is the same drug and the same manufacturer but vets in this country are not privy to the same adverse reaction information. This seems both inconsistent and alarming.'
Campaigners Demand Transparency and Action
Liz Temple, a campaigner with Librela/Solensia The Truth UK, asserts that many British pet owners are being assured by their veterinarians that Librela is entirely safe. She challenges the official stance presented by the UK's Veterinary Medicines Directorate (VMD), which currently describes the drug as 'generally safe' with 'rare side effects'.
'We do not agree,' Ms Temple stated firmly. 'Our feedback from owners shows that for hundreds of dogs, it is a killer. Many vets don't even advise of the possible side effects listed on the drug data sheet. Owners tell us they would never have consented to their dog having Librela if they'd known the real risks.'
She outlined the irreversible nature of the treatment, explaining: 'Once Librela is in a dog's system, there is no antidote. At best, it takes months to clear, at worst the side effects are so severe and ongoing that the kindest thing is to put our much-loved pets to sleep. An owner cannot give informed consent if they are not fully informed. This issue needs rectifying urgently by the VMD.'
Heartbreaking Personal Stories from Bereaved Owners
The campaign is fueled by the anguish of countless pet owners across the United Kingdom. Angela Snowball from Sunderland described her 11-year-old Springer Spaniel, Jack, as happy and healthy aside from osteoarthritis in one hind leg. 'After Jack's first and only Librela injection, he became paralysed in both back legs and completely incontinent,' she recounted. 'We tried to ride it out but it became too much for him. He died seven weeks later. Jack had so much life left to live. I will never forgive Zoetis for not being honest about this awful drug.'
In a similarly tragic case, Helen Lee of Canvey Island lost her nine-year-old French Bulldog, Frankie, just ten days after a single Librela injection in June 2025. 'Frankie went from a dog with osteoarthritis to one with severe neurological problems,' Ms Lee said. 'She lost the use of her limbs, lost her bladder control and was unaware of anyone or anything around her. It was terrible to see her suffering like that. I'm heartbroken. I agreed to her having the drug after being told it was "brilliant".' She has since enlisted her MP's support and lodged a formal complaint against the VMD.
Mounting Pressure for Regulatory Change
In response to these growing concerns, a petition on Change.org was initiated in January 2025 by Anne Chambers of Caithness, Scotland, after her own dog, Shadow, fell seriously ill following Librela treatment. The petition, which calls for a ban on the sale and use of the drug in the UK, has garnered over 4,600 signatures.
Campaigners are now demanding that the VMD follow the lead of its American counterpart. They are calling for an official letter to be issued to all UK veterinarians, detailing the full spectrum of Librela's adverse reactions, including death and euthanasia. Furthermore, they insist that pet owners should receive a comprehensive information sheet outlining all potential risks before consenting to treatment.
'The guilt, the grief and the anger that owners feel once they know the truth is tearing people apart,' Ms Temple expressed. 'They feel as if they've killed their own dog. We've called on the VMD to update its information as per the US FDA but our plea is falling on deaf ears.'
Official Responses and Industry Defence
When approached for comment, a spokesperson for the Veterinary Medicines Directorate maintained: 'We have continuously monitored Librela since it was first authorised and take all reports of adverse events seriously. Based on all available evidence, we are satisfied that the overall benefits of Librela continue to outweigh the risks for the vast majority of dogs treated with this medicine.'
Manufacturer Zoetis UK issued a robust defence of its product. In a statement, the company said: 'We continue to have full confidence in the safety and efficacy of Librela and Solensia for the alleviation of pain associated with osteoarthritis in dogs and cats. Since its launch in Europe in 2021, more than 34 million doses of Librela and 11 million doses of Solensia have been distributed globally as of December 2025 and no single reported symptom or outcome has been classified as more than 'rare to very rare' under VMD standards.'
The statement clarified that regulatory authorities in each country independently determine product labelling based on local requirements, and affirmed Zoetis's commitment to 'rigorous monitoring, transparent reporting to global regulatory agencies, and ongoing engagement with veterinarians and pet owners to support informed decision making rooted in scientific evidence.'
Despite these assurances, Dr Thompson remains unconvinced, urging a more cautious approach. 'It is fantastically naive to say any drug is safe and has no side effects. That is nonsense,' he argued. 'Librela and Solensia have a lot more side effects proportionally than a much more benign drug such as paracetamol. I'd urge UK vets to do their own research and acquaint themselves with the US FDA adverse reaction sheet and ensure they pass it on to their clients.'
This sentiment was echoed by an anonymous Gloucestershire veterinarian, who revealed the practical pressures facing the profession: 'The majority of vets are too busy and under too much pressure to read the drug data sheet information. If a drug rep tells them Librela is "safe", vets tend to just accept that without doing their own checks.'
As the debate intensifies, the central plea from campaigners and concerned experts like Dr Thompson is clear: greater transparency, improved informed consent procedures, and immediate regulatory action are essential to prevent further canine suffering and loss.
